Co-morbidités et prise en charge des cancers bronchiques: Co-morbidities and management of bronchial cancer

Abstract

Lung cancers (LC) have smoking as the main predisposing factor. Smoking behaviour has multiple consequences including cardiovascular and pulmonary diseases, and increases the risk of developing non-pulmonary cancers. Furthermore, LC occur at a later age (mean 65-67 years) in most of the cases, in a period with increased co-morbidity prevalence (diabetes, polyneuropathy, renal or hepatic diseases…).The aim of this narrative review is to set up the impact of co-morbidities on therapeutic decision and treatment choices for LC that has complexified during the last years with the introduction of multimodal and (neo)adjuvant treatments, targeted therapies, and immunotherapy. The direct roles of performance status and cardiac and lung comorbidities are the subject of other articles in this series.© 2021 SPLF. Published by Elsevier Masson SAS. All rights reserved.